FDA accepts supplemental BLA for Columvi (glofitamab) + chemotherapy combination for people with relapsed or refractory diffuse large B-cell lymphoma – Roche
Roche announced the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people… read more.